Ono Pharmaceutical Patents – Key Insights and Stats

Ono Pharmaceutical has a total of 4586 patents globally, out of which 2051 have been granted. Of these 4586 patents, more than 31% patents are active. Japan is where Ono Pharmaceutical has filed the maximum number of patents, followed by the United States of America and Europe. Parallelly, Japan seems to be the main focused R&D centre and also is the origin country of Ono Pharmaceutical.

Ono Pharmaceutical was founded in the year 1717. The Company manufactures and sells pharmaceutical products. The Company mainly researches and develops prescription drugs. As of March 2023, the market cap of Ono Pharmaceutical is $10.24 Billion.

Do read about some of the most popular patents of Ono Pharmaceutical which have been covered by us in this article and also you can find Ono Pharmaceutical patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Ono Pharmaceutical patent portfolio.

How many patents does the founder and the CEO of Ono Pharmaceutical have?

The founder Ichibei Ono has 0 patent and CEO Gyo Sagara has 0 patent.

How many patents does Ono Pharmaceutical have?

Ono Pharmaceutical has a total of 4586 patents globally. These patents belong to 929 unique patent families. Out of 4586 patents, 1467 patents are active.

How Many Patents did Ono Pharmaceutical File Every Year?

Ono Pharmaceutical Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantOno Pharmaceutical Applications FiledOno Pharmaceutical Patents Granted
20239
20223876
202110586
2020160107
2019186131
2018129107
2017163141
2016179117
201516898
2014206108
2013131119
2012191114

Explore the top-performing drugs that dominate the Pharmaceutical Industry

Patent NumberCompanyProductBrandRevenuePatent Expiry Date
US9174975Sumitomo PharmaLurasidone HydrochlorideLatuda$1.75BJun-26
US7612199AlfasigmaRifaximinXifaxan$1.64BNov-24
US7902206AlfasigmaRifaximinXifaxan$1.64BNov-24
US8158644AlfasigmaRifaximinXifaxan$1.64BNov-24
US7371727Ironwood PharmaLinaclotideLinzess$1.00BMar-25

How many Ono Pharmaceutical patents are Alive/Dead?

Ono Pharmaceutical Patents Portfolio

How Many Patents did Ono Pharmaceutical File in Different Countries?

Ono Pharmaceutical Worldwide Patents

Countries in which Ono Pharmaceutical Filed Patents

CountryPatents
Japan658
United States Of America546
Europe414
Australia202
Korea (South)188
Germany174
Taiwan154
China140
Spain132
Canada114
Mexico114
Brazil111
Russia109
South Africa104
Israel84
Norway83
India81
New Zealand77
Denmark65
Austria64
Portugal62
Hungary61
Hong Kong (S.A.R.)60
Singapore57
Poland54
Indonesia49
Viet Nam48
Philippines40
Malaysia39
Macao18
Italy18
Turkey11
Czech Republic10
Argentina6
Malta5
Morocco5
Lithuania4
Slovenia4
United Kingdom4
Peru4
Cyprus3
Luxembourg3
Chile3
Albania2
San Marino2
Iceland2
Ecuador2
Dominican Republic2
Croatia2
Serbia2
Jordan1
Eurasia1
Africa1
Bolivia1
Brunei1
Uruguay1

Where are the Research Centres of Ono Pharmaceutical Patents Located?

Research Centres of Ono Pharmaceutical Patents

10 Best Ono Pharmaceutical Patents

WO2006121168A1 is the most popular patent in the Ono Pharmaceutical portfolio. It has received 2326 citations so far from companies like Genentech, Amplimmune, and Novartis.

Below is the list of 10 most cited patents of Ono Pharmaceutical:

Publication NumberCitation Count
WO2006121168A12326
WO2004004771A1783
US7595048B2513
WO2004072286A1444
US8168179B2409
WO2004026873A1314
US8728474B2287
US20020193567A1271
US20060004010A1209
US9073994B2200

How many inventions of other companies were rejected due to Ono Pharmaceutical patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Ono Pharmaceutical invention. They couldn’t because Ono Pharmaceutical had protected those before them.

Examiners at the USPTO referred 94 Ono Pharmaceutical patents in 289 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the Ono Pharmaceutical patent portfolio are National Institutes Of Health, Wellesley Pharmaceuticals and Novartis.

List of the Companies whose Patents were rejected citing Ono Pharmaceutical –

CompanyNumber of Patent Applications that faced Rejection Citing Ono Pharmaceutical PatentsNumber of Rejections (102 & 103)
National Institutes Of Health46
Wellesley Pharmaceuticals46
Novartis49
Allergan44
Merck Sharp & Dohme44
Omeros Corporation37
Ganymed Pharmaceuticals34
Yale University23
Pharmacyclics26
Osaka University24

Count of 102 and 103 Type Rejections based on Ono Pharmaceutical Patents

Top Ono Pharmaceutical Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US7595048B216
US8460886B25
US7968572B25
US7378428B24
US20020065394A14
US20080057115A14
US8728474B24
US7288558B24
US6624193B13
US20050119305A13
US7491748B23
US8575134B23
US7344861B23
US7151093B23
US20020086364A12

What Percentage of Ono Pharmaceutical US Patent Applications were Granted?

Ono Pharmaceutical (Excluding its subsidiaries) has filed 466 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 293 have been granted leading to a grant rate of 68.14%.

Below are the key stats of Ono Pharmaceutical patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Ono Pharmaceutical?

Law FirmTotal ApplicationsSuccess Rate
Sughrue 26555018066.03%
Sughrue Mion6542.86%
Sughrue Mion Zinn Macpeak & Seas3982.05%
Stevens Davis Miller & Mosher2473.91%
Wenderoth Lind & Ponack2163.16%
Sterne Kessler Goldstein & Fox1793.75%
Foley & Lardner1484.62%
Cpa Global10100.00%
Millen White Zelano & Branigan771.43%
Sughrue Mion Zinn750.00%

What are Ono Pharmaceutical’s key innovation segments?

What Technologies are Covered by Ono Pharmaceutical?

The chart below distributes patents filed by Ono Pharmaceutical in different countries on the basis of the technology protected in patents. It also represents the markets where Ono Pharmaceutical thinks it’s important to protect particular technology inventions.

R&D Focus: How has Ono Pharmaceutical‘s search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Ono Pharmaceutical?

Table of Content

Insights you may find interesting

Related Articles

Normet Patents – Insights & Stats (Updated 2024)

Normet has a total of 164 patents globally, out of which 121 have been granted. Of these 164 patents, more than 87% patents are active. Europe (EPO) is where Normet has filed the maximum number of patents, followed by Australia and Canada. Parallelly, Finland seems to be the main focused

Read More »

Hive Box Patents – Insights & Stats (Updated 2024)

Hive Box has a total of 733 patents globally, out of which 448 have been granted. Of these 733 patents, more than 63% patents are active. China is where Hive Box has filed the maximum number of patents, followed by Korea (South). Parallelly, China seems to be the main focused

Read More »

Greensill Patents – Insights & Stats (Updated 2024)

Greensill has a total of 38 patents globally, out of which all the patents have been granted. Of these 38 patents, all the patents are active. Europe (EPO) and United Kingdom is where Greensill has filed the maximum number of patents. Parallelly, Europe (EPO) seems to be the main focused

Read More »

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.